FDA Approves Wearable That Tracks Blood Sugar and Ketones in Diabetes Patients
Continuous ketone tracking gives type 1 diabetes patients a way to catch dangerous ketoacidosis early, a capability single-point measurements could not offer.
Reporting from 1 source: GIGAZINE.
The U.S. FDA approved the Libre Duo 10 Day, a wearable device from Abbott that continuously monitors both blood sugar and ketone levels in diabetes patients. The device measures both metrics every minute and sends alerts when values hit set thresholds. Abbott plans a U.S. launch during 2026.
The device measures glucose and ketones in the fluid just beneath the skin every minute, day and night, and transmits the data wirelessly to a smartphone. It is intended for patients aged 2 and older and can be worn for up to 10 days.
Abbott says it is working with major insulin pump manufacturers to enable integration with automated insulin delivery systems in the future. The company plans to launch the device in the United States during 2026.
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.